The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk

Li Jiao; Manal M. Hassan; Melissa L. Bondy; James L. Abbruzzese; Douglas B. Evans; Donghui Li

doi:10.1016/j.canlet.2005.12.026

The XPD Asp³¹²Asn and Lys⁷⁵¹Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk

Li Jiao
, Manal M. Hassan
, Melissa L. Bondy
, James L. Abbruzzese
, Douglas B. Evans
, Donghui Li

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

We evaluated the association between the XPD exon 10 Asp³¹²Asn and exon 23 Lys⁷⁵¹Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn³¹²Asn genotype had a significantly reduced risk when compared with those carrying the ³¹²Asp allele (OR=0.46, 95% confidence interval 0.24-0.88) (P for interaction=0.03). The ³¹²Asp-⁷⁵¹Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.

Original language	English (US)
Pages (from-to)	61-68
Number of pages	8
Journal	Cancer Letters
Volume	245
Issue number	1-2
DOIs	https://doi.org/10.1016/j.canlet.2005.12.026
State	Published - Jan 8 2007

Keywords

Pancreatic cancer
Single nucleotide polymorphism
Smoking
XPD

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.canlet.2005.12.026

Cite this

@article{11c9dc64e52e4a3dbda0dca5e52ccb6e,

title = "The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk",

abstract = "We evaluated the association between the XPD exon 10 Asp312Asn and exon 23 Lys751Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn312Asn genotype had a significantly reduced risk when compared with those carrying the 312Asp allele (OR=0.46, 95\% confidence interval 0.24-0.88) (P for interaction=0.03). The 312Asp-751Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.",

keywords = "Pancreatic cancer, Single nucleotide polymorphism, Smoking, XPD",

author = "Li Jiao and Hassan, \{Manal M.\} and Bondy, \{Melissa L.\} and Abbruzzese, \{James L.\} and Evans, \{Douglas B.\} and Donghui Li",

note = "Funding Information: We thank all of the study participants. We are grateful for the laboratory support of Ping Chang, Jijiang Zhu, Yanan Li, and Yingqiu Du. We also appreciate the fieldwork conducted by Rabia Khan, Kaustubh Mestry, Ajay Nooka, and Hui Liu. We thank all of the physicians and clinical staff at the M.D. Anderson Gastrointestinal Center who helped with patient recruitment. We thank Don Norwood for scientific editing. This study was supported by National Institutes of Health grant CA98380, National Institute of Environmental Health Sciences grant P30 ES07784, National Institutes of Health Cancer Center Support (Core) Grant CA16672, and a research grant from M.D. Anderson. ",

year = "2007",

month = jan,

day = "8",

doi = "10.1016/j.canlet.2005.12.026",

language = "English (US)",

volume = "245",

pages = "61--68",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1-2",

}

TY - JOUR

T1 - The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk

AU - Jiao, Li

AU - Hassan, Manal M.

AU - Bondy, Melissa L.

AU - Abbruzzese, James L.

AU - Evans, Douglas B.

AU - Li, Donghui

N1 - Funding Information: We thank all of the study participants. We are grateful for the laboratory support of Ping Chang, Jijiang Zhu, Yanan Li, and Yingqiu Du. We also appreciate the fieldwork conducted by Rabia Khan, Kaustubh Mestry, Ajay Nooka, and Hui Liu. We thank all of the physicians and clinical staff at the M.D. Anderson Gastrointestinal Center who helped with patient recruitment. We thank Don Norwood for scientific editing. This study was supported by National Institutes of Health grant CA98380, National Institute of Environmental Health Sciences grant P30 ES07784, National Institutes of Health Cancer Center Support (Core) Grant CA16672, and a research grant from M.D. Anderson.

PY - 2007/1/8

Y1 - 2007/1/8

N2 - We evaluated the association between the XPD exon 10 Asp312Asn and exon 23 Lys751Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn312Asn genotype had a significantly reduced risk when compared with those carrying the 312Asp allele (OR=0.46, 95% confidence interval 0.24-0.88) (P for interaction=0.03). The 312Asp-751Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.

AB - We evaluated the association between the XPD exon 10 Asp312Asn and exon 23 Lys751Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn312Asn genotype had a significantly reduced risk when compared with those carrying the 312Asp allele (OR=0.46, 95% confidence interval 0.24-0.88) (P for interaction=0.03). The 312Asp-751Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.

KW - Pancreatic cancer

KW - Single nucleotide polymorphism

KW - Smoking

KW - XPD

UR - https://www.scopus.com/pages/publications/33845624102

UR - https://www.scopus.com/pages/publications/33845624102#tab=citedBy

U2 - 10.1016/j.canlet.2005.12.026

DO - 10.1016/j.canlet.2005.12.026

M3 - Article

C2 - 16458430

AN - SCOPUS:33845624102

SN - 0304-3835

VL - 245

SP - 61

EP - 68

JO - Cancer Letters

JF - Cancer Letters

IS - 1-2

ER -